Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q4 2017 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, November 2017
Slide 1: Agilent Technologies Q4'17 Results Presentation
Agilent Technologies Q4'17 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, operating profit and operating margin, expected cash flow, growth opportunities, customer service and innovation plans, new
Slide 3: Agilent Results Q4'17
Agilent Results Q4'17 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q4'17 Financial Metrics FY17 Headlines • Revenues: $1.19B, +5.8% y/y core(1)(2),+7.1% • Growth: FY17 Core growth(1)(2) finished at +6.7%, reported (+0.3% M&A, +1.0% FX). Core growth +6.4% repo
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) Instrumentation and Informatics • Core revenue growth led by demand for Analytical Laboratories in Europe with strength in Chemical & Energy, Academia & Government and Food offsetting declines in Pharma. • Operating Margin for the quarter was 23.9%(1)(2),
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Continued strong revenue performance. Consumables and Services Growth was healthy across services and consumables, most regions and end-markets.. • Operating Margin in the quarter was 22.9%(1)(2), up 20 bps versus last year. • Agilent’s Cross Lab
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and • Demand was strong for pathology products Nucleic Acid Manufacturing and companion diagnostics services. Continued strength for PD-L1 and molecular products. Japan and China led regional gains. • Operating Margin for the quarter was 20.8
Slide 7: Growth in a $21B Market – Q4'17 Results by End Market
Growth in a $21B Market(1) – Q4'17 Results by End Market Gains highlighted by robust Chemical/Energy, Academic/Government, and Food results offsetting softness in Pharma Analytical Laboratory End Markets Agilent Revenue by End Market (2) Q4'17 revenues: +5% y/y on core(3) basis Pharma & Biotech:
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions Delivering on “Agile Agilent” Initiatives • Multi-year program to increase efficiency and customer focus. Operating Margin up year-over-year – 11th consecutive quarter. Portfolio Investments and “Go-to-Market” Capability • Acquired Cobalt Light Syste
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value Above Market Growth • Innovative, highly differentiated new products and solutions • Win enterprise lab-wide services & consumables - CrossLab • Accelerate bio-pharma penetration • Drive adoption of clinical genomics applications Aggressively ex
Slide 10: Q1'18 and FY18 Guidance and Forward-looking Considerations
Q1’18 and FY18 Guidance and Forward-looking Considerations Based on October 31, 2017 Exchange Rates FY18 FY18 Guidance FY17 Guidance at • Revenue: $4.72B - $4.74B: growth at mid-point 4.25% core(4), 5.8% Actual (2) mid-point reported (1) (+0.2% M&A, +1.3% FX) (1)(2) • Operating Margin: 22.2% at mid-